Market Analysis: Global Pyelonephritis Treatment Market
Market Definition: Global Pyelonephritis Treatment Market
Pyelonephritis is also known as kidney infection is characterized by infections of one or both side of kidney. It can lead to permanently damage to the kidney and can cause a life-threatening infection. People with kidney infection may experience fever, abdominal pain strong, persistent urge to urinate and nausea etc.
Get More Insights About Global Pyelonephritis Treatment Market, Request Sample @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pyelonephritis-treatment-market
Growing prevalence of kidney infections and injuries worldwide is drive the market growth
Huge financial support to the researchers for developing novel intervention is boosting the market growth
High demand of disease specific novel treatment can also act as a market driver
Recent launch of product and emerging new market is propelling g the market growth
Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
Low healthcare budget in some developing countries is hamper the market growth
Know more about this report https://www.databridgemarketresearch.com/reports/global-pyelonephritis-treatment-market
Segmentation: Global Pyelonephritis Treatment Market
Meropenem and Vaborbactam
By Route of Administration
By End Users
By Distribution Channel
Rest of South America
Rest of Europe
Rest of Asia Pacific
Middle East & Africa
Rest of Middle East & Africa
Key Developments in the Market:
In July 2019, Cipla USA Inc, a subsidiary of Cipla Inc acquired worldwide rights excluding Greater China for prescription drug Zemdri (Plazomicin), an aminoglycoside antibacterial for the treatment of complicated Urinary Tract Infections (cUTI) including pyelonephritis from Achaogen Inc. The acquisition of Zemdri, expands the company’s infectious portfolio as well as represent major advances in the treatment of these patients through a targeted mode of action.
In November 2018, MELINTA THERAPEUTICS, INC received approval from the European Commission (EC) for Vabomere (meropenem and vaborbactam) for the treatment of complicated intra-abdominal (cIAI) and urinary tract infections (cUTI) including pyelonephritis and hospital-acquired pneumonia including ventilator associated pneumonia. The approval of Vabomere has significantly changed the treatment landscape for underserved patient population.
Key Market Players:
Few of the major competitors currently working in the global pyelonephritis treatment market are MELINTA THERAPEUTICS, INC, Cipla Inc, Johnson & Johnson Services, Inc, Allecra Therapeutics, Entasis Therapeutics, Pfizer Inc, Allergan, Paratek Pharmaceuticals Inc, Spero Therapeutics, MerLion Pharmaceuticals GmbH, Merck & Co., Inc, VenatoRx Pharmaceuticals, Inc, Venus Remedies Limited, Nabriva Therapeutics plc, Shionogi Inc, Bayer AG, Takeda Pharmaceutical Company Limited and others.
Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.
Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.
Request for Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-pyelonephritis-treatment-market
Browse Trending Related Reports @
About Data Bridge Market Research: